

# EGFRVIII

Catalog # PVGS1841

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">NP_001333870.1</a> Human
<b>Sequence</b>	Leu25-Ser378
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Biological Activity</b>	Immobilized EGFRVIII, His&Avi, Human (Cat.No.: Z03940) at 1 $\mu$ g/ml (100 $\mu$ l/Well) on the plate can bind Anti-EGFRVIII Antibody, hFc Tag.
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	41.6 kDa
<b>Formulation Reconstitution</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, (pH 7.4). It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O more than 100 $\mu$ g/ml.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF- $\alpha$ ). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy.
--------------------------	---

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.